Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma - Report - MDSpire

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

  • By

  • Laura B. Oswald

  • Xiaoyin Li

  • Lisa M. Gudenkauf

  • Gabe De Avila

  • David Scheiber-Camoretti

  • Brent J. Small

  • Brian D. Gonzalez

  • Aasha I. Hoogland

  • Oanh Nguyen

  • Yvelise Rodriguez

  • Sylvia L. Crowder

  • Nathan H. Parker

  • Tiffany L. Carson

  • Christine E. Vinci

  • Rachid C. Baz

  • Kenneth H. Shain

  • Brandon Blue

  • Ariel Grajales-Cruz

  • Kristy Matte

  • Brandon Kale

  • David Kaldas

  • Fabiana Perna

  • Melissa Alsina

  • Ciara L. Freeman

  • Omar Castaneda Puglianini

  • Taiga Nishihori

  • Hien Liu

  • Frederick L. Locke

  • Heather S. L. Jim

  • Lauren C. Peres

  • Doris K. Hansen

  • May 11, 2026

  • 0 min

Share

Clinical Report: Comparative Analysis of Patient-Reported Outcomes Following CAR-T Therapy

Overview

This study evaluates patient-reported outcomes (PROs) in relapsed/refractory multiple myeloma patients receiving idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) CAR-T therapy. Findings indicate that while many PROs initially worsened, significant improvements were observed post-treatment, with notable differences in social well-being and cognitive function trajectories between treatment groups.

Background

Chimeric antigen receptor T-cell therapy (CAR-T) has emerged as a transformative treatment for relapsed/refractory multiple myeloma (RRMM), with ide-cel and cilta-cel showing promising efficacy. Understanding patient-reported outcomes (PROs) is crucial as these measures reflect the patient's perspective on their health-related quality of life (HRQOL) and symptom burden, which are essential for comprehensive care. This study addresses the gap in longitudinal PRO data comparing these two CAR-T therapies.

Data Highlights

MeasurePre-D7Post-D7
Overall HRQOLWorsenedImproved
Physical Well-BeingWorsenedImproved
Functional Well-BeingWorsenedImproved
FatigueWorsenedImproved
AnxietyStableImproved

Key Findings

  • PROs worsened pre-D7 and improved post-D7 for multiple measures including overall HRQOL and physical well-being.
  • Patients receiving ide-cel were older than those receiving cilta-cel (median age 73 vs. 64 years, p < 0.001).
  • Differences in social well-being trajectories were observed pre-D7 (p = 0.01) between treatment groups.
  • Cognitive function showed significant improvement post-D7 for both groups, with differences noted (p = 0.001).
  • Overall, PRO trajectories were similar between ide-cel and cilta-cel recipients, with most measures improving significantly post-treatment.

Clinical Implications

Clinicians should consider the initial worsening of PROs following CAR-T therapy, which may impact patient expectations and management strategies. The observed differences in social well-being and cognitive function trajectories suggest the need for tailored supportive care interventions based on the specific CAR-T treatment received.

Conclusion

This study highlights the importance of monitoring PROs in patients undergoing CAR-T therapy for RRMM, revealing significant improvements post-treatment that can inform clinical practice and patient counseling.

Related Resources & Content

  1. Hansen et al., Journal of Clinical Oncology, 2023 -- Idecabtagene Vicleucel vs Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
  2. Rodriguez-Otero et al., The New England Journal of Medicine, 2023 -- Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
  3. Current Developments and Future Obstacles of CAR-T Cell Therapy in Multiple Myeloma, Blood Cancer Journal, 2024
  4. Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma, The ASCO Post, 2026
  5. NCCN Clinical Practice Guidelines In Oncology - Multiple Myeloma, Version 5.2026
  6. Current Context on Patient-Reported Outcomes with CAR-T Therapy
  7. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial - PubMed
  8. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies - PMC

Original Source(s)

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

  • by Laura B. Oswald, Xiaoyin Li, Lisa M. Gudenkauf, Gabe De Avila, David Scheiber-Camoretti, Brent J. Small, Brian D. Gonzalez, Aasha I. Hoogland, Oanh Nguyen, Yvelise Rodriguez, Sylvia L. Crowder, Nathan H. Parker, Tiffany L. Carson, Christine E. Vinci, Rachid C. Baz, Kenneth H. Shain, Brandon Blue, Ariel Grajales-Cruz, Kristy Matte, Brandon Kale, David Kaldas, Fabiana Perna, Melissa Alsina, Ciara L. Freeman, Omar Castaneda Puglianini, Taiga Nishihori, Hien Liu, Frederick L. Locke, Heather S. L. Jim, Lauren C. Peres, Doris K. Hansen

  • May 11, 2026

Related Content

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

High-grade astrocytoma with piloid features: a case report of comprehensive management

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential